Streetbeat News

ZEAL

Zealand Pharma A/S.

https://www.zealandpharma.com/

CEO

Emmanuel Dulac

Employees

329

Industry

Pharmaceutical Preparation Manufacturing

Open

18.03

Mkt cap

N/A

Volume

2.2K

High

18.07

P/E Ratio

N/A

52-wk high

32.12

Low

17.47

Div yield

N/A

52-wk low

9.93

The FDA has issued a Complete Response Letter to Zealand Pharma for their New Drug Application for glepaglutide, indicating that the application did not meet the necessary requirements for efficacy and safety.

Portfolio Pulse from

December 19, 2024 | 8:15 pm

Zealand Pharma has enrolled the first participant in its Phase 2b ZUPREME-1 trial for petrelintide, targeting overweight or obesity. This marks a significant step in the development of their treatment.

Portfolio Pulse from

December 10, 2024 | 2:15 pm

Zealand Pharma A/S announced its participation in the Jefferies London Healthcare Conference, which could provide exposure and networking opportunities for the company.

Portfolio Pulse from

November 13, 2024 | 5:15 pm

Zealand Pharma announced transactions in its shares by persons with managerial responsibilities or their associates.

Portfolio Pulse from

November 11, 2024 | 4:15 pm

Zealand Pharma has increased its share capital by DKK 10,110 through the exercise of employee warrants, resulting in the issuance of 10,110 new shares.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 3:03 pm

Zealand Pharma announced positive results from a Phase 1b trial of dapiglutide, showing significant weight reduction and good tolerability. The trial is ongoing with higher doses being tested, and results are expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 3:04 pm

Zealand Pharma has increased its share capital by DKK 13,000 through the exercise of employee warrants, resulting in the issuance of 13,000 new shares.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 8:13 pm

Zealand Pharma (NASDAQ: ZEAL) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its dasiglucagon solution for injection, intended for the treatment of severe hypoglycemia in diabetes patients. This recommendation is a significant step towards obtaining marketing authorization in Europe.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 2:11 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.